相似文献
1
Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system - An overlooked association?
Eur J Intern Med. 2020 Oct;80:106-107. doi: 10.1016/j.ejim.2020.06.012. Epub 2020 Jun 12.
2
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
3
COVID-19 challenging cell biology.
Protoplasma. 2020 May;257(3):619-620. doi: 10.1007/s00709-020-01506-z. Epub 2020 Apr 24.
4
The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
Hellenic J Cardiol. 2020 Jan-Feb;61(1):31-33. doi: 10.1016/j.hjc.2020.05.003. Epub 2020 May 22.
5
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.
6
SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments.
Infect Disord Drug Targets. 2020;20(3):348-349. doi: 10.2174/1871526520999200505174704.
7
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
8
Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications.
Cardiovasc Res. 2020 Jun 1;116(7):e87-e89. doi: 10.1093/cvr/cvaa096.
9
Effects of Renin-Angiotensin Inhibition on ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Protease Serine 2) Expression: Insights Into COVID-19.
Hypertension. 2020 Oct;76(4):e29-e30. doi: 10.1161/HYPERTENSIONAHA.120.15782. Epub 2020 Jul 14.
10
Is COVID-19 more severe in older men?
Postgrad Med J. 2020 Jul;96(1137):426. doi: 10.1136/postgradmedj-2020-137867. Epub 2020 May 13.
本文引用的文献
1
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Eur J Intern Med. 2020 Jun;76:14-20. doi: 10.1016/j.ejim.2020.04.037. Epub 2020 Apr 20.
2
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Ann Rheum Dis. 2020 Jun;79(6):837-839. doi: 10.1136/annrheumdis-2020-217566. Epub 2020 Apr 24.
3
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.
Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.
4
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.
Ann Rheum Dis. 2020 May;79(5):668-669. doi: 10.1136/annrheumdis-2020-217442. Epub 2020 Apr 2.
5
Speculation is not evidence: antihypertensive therapy and COVID-19.
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):133-134. doi: 10.1093/ehjcvp/pvaa021.
6
Angiotensin Converting Enzyme 2: A Double-Edged Sword.
Circulation. 2020 Aug 4;142(5):426-428. doi: 10.1161/CIRCULATIONAHA.120.047049. Epub 2020 Mar 26.
7
Sex difference and smoking predisposition in patients with COVID-19.
Lancet Respir Med. 2020 Apr;8(4):e20. doi: 10.1016/S2213-2600(20)30117-X. Epub 2020 Mar 11.
8
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
9
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Clin Sci (Lond). 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163.
10
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.
Crit Care. 2017 Sep 7;21(1):234. doi: 10.1186/s13054-017-1823-x.
Zotero 插件